Colgate-Palmolive (NYSE:CL) Shares Purchased by Apeiron RIA LLC

Apeiron RIA LLC boosted its stake in shares of Colgate-Palmolive (NYSE:CL) by 5.1% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 7,745 shares of the company’s stock after buying an additional 379 shares during the quarter. Apeiron RIA LLC’s holdings in Colgate-Palmolive were worth $704,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently added to or reduced their stakes in the stock. XTX Topco Ltd purchased a new stake in shares of Colgate-Palmolive in the 2nd quarter worth about $423,000. Evergreen Capital Management LLC grew its position in shares of Colgate-Palmolive by 4.2% in the second quarter. Evergreen Capital Management LLC now owns 3,490 shares of the company’s stock valued at $339,000 after purchasing an additional 141 shares during the last quarter. AlTi Global Inc. increased its stake in shares of Colgate-Palmolive by 2.9% during the 2nd quarter. AlTi Global Inc. now owns 4,281 shares of the company’s stock worth $415,000 after purchasing an additional 119 shares in the last quarter. AQR Capital Management LLC raised its position in shares of Colgate-Palmolive by 58.6% during the 2nd quarter. AQR Capital Management LLC now owns 2,416,943 shares of the company’s stock worth $234,540,000 after purchasing an additional 892,706 shares during the last quarter. Finally, APG Asset Management N.V. lifted its stake in Colgate-Palmolive by 64.3% in the 2nd quarter. APG Asset Management N.V. now owns 1,251,422 shares of the company’s stock valued at $113,308,000 after buying an additional 489,977 shares in the last quarter. 80.41% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, CFO Stanley J. Sutula III sold 45,410 shares of the business’s stock in a transaction that occurred on Tuesday, November 5th. The stock was sold at an average price of $94.11, for a total transaction of $4,273,535.10. Following the transaction, the chief financial officer now directly owns 36,726 shares of the company’s stock, valued at approximately $3,456,283.86. The trade was a 55.29 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 0.34% of the stock is currently owned by insiders.

Colgate-Palmolive Price Performance

Colgate-Palmolive stock opened at $87.98 on Friday. The company has a quick ratio of 0.68, a current ratio of 1.04 and a debt-to-equity ratio of 9.46. The firm has a market capitalization of $71.88 billion, a P/E ratio of 25.21, a PEG ratio of 3.62 and a beta of 0.44. The firm has a fifty day moving average of $92.00 and a 200-day moving average of $97.58. Colgate-Palmolive has a 52-week low of $80.03 and a 52-week high of $109.30.

Colgate-Palmolive Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, February 14th. Shareholders of record on Tuesday, January 21st will be given a $0.50 dividend. This represents a $2.00 annualized dividend and a yield of 2.27%. The ex-dividend date of this dividend is Tuesday, January 21st. Colgate-Palmolive’s dividend payout ratio (DPR) is presently 57.31%.

Analysts Set New Price Targets

CL has been the subject of a number of analyst reports. Barclays cut their price target on Colgate-Palmolive from $96.00 to $83.00 and set an “equal weight” rating for the company in a report on Friday, January 17th. JPMorgan Chase & Co. cut their target price on shares of Colgate-Palmolive from $109.00 to $103.00 and set an “overweight” rating for the company in a research note on Thursday, January 16th. UBS Group decreased their price target on shares of Colgate-Palmolive from $112.00 to $104.00 and set a “buy” rating on the stock in a research note on Thursday, January 16th. TD Cowen cut their price objective on shares of Colgate-Palmolive from $110.00 to $100.00 and set a “buy” rating for the company in a research report on Wednesday, January 8th. Finally, Stifel Nicolaus decreased their target price on shares of Colgate-Palmolive from $101.00 to $95.00 and set a “hold” rating on the stock in a research report on Friday, January 17th. One equities research analyst has rated the stock with a sell rating, ten have issued a hold rating and twelve have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $101.11.

Colgate-Palmolive Profile

Colgate-Palmolive Company, together with its subsidiaries, manufactures and sells consumer products in the United States and internationally. It operates through two segments: Oral, Personal and Home Care; and Pet Nutrition. The Oral, Personal and Home Care segment offers toothpaste, toothbrushes, mouthwash, bar and liquid hand soaps, shower gels, shampoos, conditioners, deodorants and antiperspirants, skin health products, dishwashing detergents, fabric conditioners, household cleaners, and other related items.